Bristol-Myers Squibb (NYSE:BMY) Shares Sold by FARMERS & MERCHANTS TRUST Co OF LONG BEACH

FARMERS & MERCHANTS TRUST Co OF LONG BEACH trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 10.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,308 shares of the biopharmaceutical company’s stock after selling 515 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Bristol-Myers Squibb were worth $263,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. LaFleur & Godfrey LLC lifted its stake in shares of Bristol-Myers Squibb by 3.5% in the 4th quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company’s stock valued at $2,463,000 after purchasing an additional 1,487 shares during the period. Brighton Jones LLC lifted its stake in shares of Bristol-Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares during the period. Bank Pictet & Cie Europe AG acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $13,094,000. Roxbury Financial LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $60,000. Finally, Montag A & Associates Inc. lifted its stake in shares of Bristol-Myers Squibb by 319.2% in the 4th quarter. Montag A & Associates Inc. now owns 89,258 shares of the biopharmaceutical company’s stock valued at $5,048,000 after purchasing an additional 67,966 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Samit Hirawat acquired 4,250 shares of the company’s stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares of the company’s stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Price Performance

Bristol-Myers Squibb stock opened at $49.71 on Monday. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The company has a fifty day simple moving average of $48.71 and a 200-day simple moving average of $54.70. The firm has a market capitalization of $101.15 billion, a price-to-earnings ratio of -11.25, a PEG ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter in the prior year, the firm posted ($4.40) earnings per share. Bristol-Myers Squibb’s quarterly revenue was down 5.6% on a year-over-year basis. On average, equities analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BMY has been the subject of a number of research analyst reports. Cantor Fitzgerald restated a “neutral” rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Argus upgraded shares of Bristol-Myers Squibb to a “hold” rating in a research report on Friday, April 25th. The Goldman Sachs Group restated a “neutral” rating and set a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Finally, Piper Sandler initiated coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.